Detalhe da pesquisa
1.
Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors.
ACS Pharmacol Transl Sci
; 5(11): 1156-1168, 2022 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36407952
2.
Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status.
Cancers (Basel)
; 12(7)2020 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32630796